These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36408587)

  • 1. A review of berotralstat for the treatment of hereditary angioedema.
    Farkas H; Balla Z
    Expert Rev Clin Immunol; 2023 Feb; 19(2):145-153. PubMed ID: 36408587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
    Johnson F; Stenzl A; Hofauer B; Heppt H; Ebert EV; Wollenberg B; Lochbaum R; Hahn J; Greve J; Trainotti S
    Clin Rev Allergy Immunol; 2023 Dec; 65(3):354-364. PubMed ID: 37914894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.
    Manning ME; Kashkin JM
    Allergy Asthma Proc; 2021 Jul; 42(4):274-282. PubMed ID: 34127176
    [No Abstract]   [Full Text] [Related]  

  • 4. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
    Kiani-Alikhan S; Gower R; Craig T; Wedner HJ; Kinaciyan T; Aygören-Pürsün E; Banerji A; Bernstein JA; Anderson J; Collis P; Johnston DT; Desai B; Tomita D; Gagnon R; Tachdjian R; Soteres DF; Farkas H; Caballero T; McNeil D; Jacobs J; Lumry WR;
    J Allergy Clin Immunol Pract; 2024 Mar; 12(3):733-743.e10. PubMed ID: 38122865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
    Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
    Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orladeyo (Berotralstat): A Novel Oral Therapy for the Prevention of Hereditary Angioedema.
    Powell J; Piszczatoski C; Rubido E
    Ann Pharmacother; 2022 Apr; 56(4):488-493. PubMed ID: 34282650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.
    Zuraw B; Lumry WR; Johnston DT; Aygören-Pürsün E; Banerji A; Bernstein JA; Christiansen SC; Jacobs JS; Sitz KV; Gower RG; Gagnon R; Wedner HJ; Kinaciyan T; Hakl R; Hanzlíková J; Anderson JT; McNeil DL; Fritz SB; Yang WH; Tachdjian R; Busse PJ; Craig TJ; Li HH; Farkas H; Best JM; Clemons D; Cornpropst M; Dobo SM; Iocca HA; Kargl D; Nagy E; Murray SC; Collis P; Sheridan WP; Maurer M; Riedl MA
    J Allergy Clin Immunol; 2021 Jul; 148(1):164-172.e9. PubMed ID: 33098856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat.
    Riedl MA; Soteres D; Sublett JW; Desai B; Tomita D; Collis P; Bernstein JA;
    Ann Allergy Asthma Immunol; 2024 Apr; 132(4):505-511.e1. PubMed ID: 38006972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency.
    Jacobs J; Neeno T
    Postgrad Med; 2021 Aug; 133(6):639-650. PubMed ID: 33993830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical study results of Berotralstat Hydrochloride for long-term prophylactic treatment of hereditary angioedema].
    Orui S; Nozue H; Kobayashi S; Fujioka M; Maekawa Y
    Nihon Yakurigaku Zasshi; 2021; 156(6):382-390. PubMed ID: 34719573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.
    Srinivasan C; Ritchie B; Adatia A
    Front Immunol; 2024; 15():1339421. PubMed ID: 38318176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of oral kallikrein inhibitor berotralstat for hereditary angioedema.
    Gao Y; Hwang J; Hwang G; Craig T
    Drugs Today (Barc); 2022 Feb; 58(2):59-67. PubMed ID: 35188140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S study.
    Farkas H; Stobiecki M; Peter J; Kinaciyan T; Maurer M; Aygören-Pürsün E; Kiani-Alikhan S; Wu A; Reshef A; Bygum A; Fain O; Hagin D; Huissoon A; Jeseňák M; Lindsay K; Panovska VG; Steiner UC; Zubrinich C; Best JM; Cornpropst M; Dix D; Dobo SM; Iocca HA; Desai B; Murray SC; Nagy E; Sheridan WP
    Clin Transl Allergy; 2021 Jun; 11(4):e12035. PubMed ID: 34161665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).
    Wedner HJ; Aygören-Pürsün E; Bernstein J; Craig T; Gower R; Jacobs JS; Johnston DT; Lumry WR; Zuraw BL; Best JM; Iocca HA; Murray SC; Desai B; Nagy E; Sheridan WP; Kiani-Alikhan S
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2305-2314.e4. PubMed ID: 33866032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence based therapeutic approach to hereditary and acquired angioedema.
    Bork K
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
    Sabharwal G; Craig T
    Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).
    Bork K
    Clin Rev Allergy Immunol; 2016 Oct; 51(2):183-92. PubMed ID: 27207174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hereditary angioedema-single or multiple pathways to the rescue.
    Valerieva A; Longhurst HJ
    Front Allergy; 2022; 3():952233. PubMed ID: 36172291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
    Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M
    Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.